Amgen Defies 206th Volume Rank as Institutional Buys Drive 0.66 Rally Amid FDA Hopes

On September 26, 2025, Amgen (AMGN) closed 0.66% higher despite a 35.2% drop in trading volume to $0.49 billion, ranking 206th in market activity. The biotech giant’s share price movement was driven by regulatory updates and investor positioning amid mixed sector dynamics.

Analysts noted increased institutional buying activity in the firm’s mid-cap biologics portfolio, while short interest data showed a 12% decline in open short positions over the past two weeks. Market participants attributed the volume contraction to reduced speculative trading following a recent FDA advisory panel approval for a key oncology candidate, which had already been priced into the stock.

Portfolio managers highlighted Amgen’s defensive positioning as a factor in its outperformance relative to broader biotech indices. The company’s upcoming Phase III trial readouts for its hematology franchise are expected to remain a key catalyst for near-term volatility. Technical indicators showed accumulation in the $350-$360 price corridor, suggesting institutional support levels.

To run this back-test rigorously I need to pin down a few implementation details: 1. Universe • Do we limit ourselves to all primary-listed U.S. equities (NYSE / NASDAQ / AMEX) or another universe (e.g., S&P 500, Russell 3000, global)? 2. Daily workflow • On each rebalancing day should the portfolio – rank stocks by the day’s total dollar volume (default), – buy at that day’s close and exit at next day’s close (1-day holding), or – buy at next day’s open and exit at that same day’s close? 3. Weighting & capital • Equal-weight across the 500 names (default) or volume-proportional? • Assume 100% of capital is redeployed each day (default). 4. Frictions • Any commission, bid-ask spread, or slippage assumptions to include? 5. Output format • Besides cumulative return & drawdown, do you want per-year stats or factor attribution? Because this is a cross-sectional strategy involving 500 stocks per day, it will require a portfolio back-test rather than the single-ticker tools. Once the above points are settled I’ll prepare the data-retrieval plan and run the back-test for 2022-01-01 to the present.